The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study
-
Published:2022-02
Issue:
Volume:170
Page:103596
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Santoni Matteo,
Rizzo Alessandro,
Mollica Veronica,
Matrana Marc R.,
Rosellini MatteoORCID,
Faloppi LucaORCID,
Marchetti Andrea,
Battelli Nicola,
Massari FrancescoORCID
Subject
Oncology,Hematology
Reference66 articles.
1. Role of the immune system in aging and longevity;Alonso-Fernández;Curr. Aging Sci.,2011
2. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021
3. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300;Bang;Ann. Oncol.,2018
4. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study;Barlesi;Lancet Oncol.,2018
5. KEYNOTE-045 investigators. pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N. Engl. J. Med.,2017
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献